Priority Review Voucher
Krystal’s Vyjuvek Gene Therapy Gains FDA Approval, Spurs Sales Projections
Anika Sharma
Krystal Biotech’s CEO, Krish Krishnan, was quick to highlight in the company’s inaugural conference call to present its quarterly results ...
Krystal Biotech Secures $100 Million in Sale of Priority Review Voucher
Anika Sharma
Krystal Biotech proudly announces the successful transaction of its Rare Pediatric Disease Priority Review Voucher (PRV), yielding an impressive $100 ...
Sarepta Therapeutics Sells Rare Pediatric Disease Priority Review Voucher for $102 Million to Boost Research and Development
SG Tylor
Source – Sarepta Therapeutics On July 5, 2023, Sarepta Therapeutics, a leading company in precision genetic medicine for rare diseases, ...
